Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.9K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Hazard Ratio01:12

Hazard Ratio

686
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
686
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of digital technology in non-pharmacological cognitive and psychosocial interventions for people with dementia and mild cognitive impairment: A scoping review.

PloS one·2026
Same author

Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control.

Nature metabolism·2025
Same author

A simple upgrade or a gradual retirement? A critical commentary on NASA-TLX.

Ergonomics·2025
Same author

Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.

BMC infectious diseases·2025
Same author

Accelerating Scaffold Hopping in Fourth-Generation Epidermal Growth Factor Receptor Inhibitors via Multilevel Virtual Screening.

ACS medicinal chemistry letters·2025
Same author

Discovery of novel tropomyosin receptor kinase A inhibitors by virtual screening merging ligand-based and structure-based methods.

Bioorganic & medicinal chemistry·2025
Same journal

SpaceExpander: An Automated System for Drafting Markush Claims to Expand Chemical Space.

Molecular informatics·2026
Same journal

A Structure-Informed Atlas of Venom-Derived Peptides Reveals the Organization of Chemical Space.

Molecular informatics·2026
Same journal

ConGen: Targeted Molecule Generation Through Contrastive Learning and Latent Optimization.

Molecular informatics·2026
Same journal

Novel Molecules Generation Using Graph Generative Adversarial Networks.

Molecular informatics·2026
Same journal

An Attention-Driven Graph Transformer With Nonlinear Modeling and Neuro-Fuzzy Fusion for High-Order Toxic Molecular Graph Learning.

Molecular informatics·2026
Same journal

Molecular Modeling and Chemoinformatics in Ukraine.

Molecular informatics·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

P300-Based Brain-Computer Interface Speller Performance Estimation with Classifier-Based Latency Estimation
06:09

P300-Based Brain-Computer Interface Speller Performance Estimation with Classifier-Based Latency Estimation

Published on: September 8, 2023

1.0K

Probability Based hERG Blocker Classifiers.

Zhi Wang1, Hamse Y Mussa2, Robert Lowe2

  • 1State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, 15 Bei San Huan East Road, P.O. Box 53, Beijing 100029, P. R. China telephone: +86-10-64421335, fax: +86-10-64416428.

Molecular Informatics
|August 2, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces probabilistic models for predicting human ether-a-go-go related (hERG) channel inhibition, offering a nuanced alternative to traditional yes/no drug safety assessments. These models aid in ranking compounds for potential cardio-toxicity, improving drug development safety.

Keywords:
Human ether-a-go-go related (hERG)Kernelised naive Bayes (KNB)Naive Bayes (NB)Parzen-window based model (PWM)Probabilistic classification

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.7K

Related Experiment Videos

Last Updated: Mar 17, 2026

P300-Based Brain-Computer Interface Speller Performance Estimation with Classifier-Based Latency Estimation
06:09

P300-Based Brain-Computer Interface Speller Performance Estimation with Classifier-Based Latency Estimation

Published on: September 8, 2023

1.0K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.7K

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Toxicology

Background:

  • The US Food and Drug Administration mandates in vitro human ether-a-go-go related (hERG) ion channel affinity testing for drug candidates.
  • Traditional quantitative structure-activity relationship (QSAR) models often use supervised 'hard point' classification, providing binary 'yes/no' predictions.

Purpose of the Study:

  • To develop novel probabilistic-based prediction models for hERG channel inhibition.
  • To offer a more nuanced approach than traditional binary classification methods for drug safety assessment.

Main Methods:

  • Employed probabilistic-based methods to create prediction models for hERG inhibition.
  • Developed models capable of ascertaining the likelihood of compounds blocking hERG ion channels.

Main Results:

  • The probabilistic models provide a method to 'ascertain' compound effects on hERG channels.
  • Demonstrated the utility of probabilistic models in ranking compounds based on potential cardio-toxicity.

Conclusions:

  • Probabilistic-based methods are valuable for predicting hERG inhibition and ranking compounds for cardio-toxicity.
  • The approach shows promise for predicting other toxic properties in drug development.